Yuflyma
Payments companies reported to CMS as associated with Yuflyma. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Yuflyma, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Yuflyma
These are the largest totals companies reported as associated with Yuflyma. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Luis Arias-Urdaneta | Miami Shores, FL | Rheumatology | $154.58 |
| Kent Ta | Bellevue, WA | Rheumatology | $131.75 |
| Robert Scofield | Oklahoma City, OK | Endocrinology, Diabetes & Metabolism | $112.69 |
| Yesenia Santiago-Casas | Hollywood, FL | Rheumatology | $111.40 |
| Annette Kwon | San Francisco, CA | Gastroenterology (Internal Medicine) | $99.65 |
| Kurt Oelke | Glendale, WI | Rheumatology | $99.22 |
| Yezaz Ghouri | Columbia, MO | Gastroenterology (Internal Medicine) | $95.36 |
| Asmeen Bhatt | Houston, TX | Gastroenterology (Internal Medicine) | $95.36 |
| Jill Gaidos | New Haven, CT | Gastroenterology (Internal Medicine) | $95.36 |
| Ahmed Ibrahem Ahmed Swi | Columbia, MO | Gastroenterology (Internal Medicine) | $95.36 |
Prescribed Yuflyma?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.